tPA-ROTEM identifies hyperfibrinolytic profile in a significant proportion of patients with bleeding disorder of unknown cause (BDUC).
A L L Monard, D Hellenbrand, P Verhezen...
https://pubmed.ncbi.nlm.nih.gov/40680469/Actively Recruiting
Led by Maastricht University Medical Center · Updated on 2026-10-13
500
Participants Needed
8
Research Sites
N/A
Total Duration
Researchers are studying individuals with a bleeding disorder of unknown cause BDUC, a condition where people experience increased bleeding but standard lab tests do not identify a specific cause. This study aims to better understand the reasons behind unexplained bleeding in BDUC, how it affects daily life and health-related quality of life, and how care for these patients can be improved. The study is observational and involves multiple centers in the Netherlands. Participants aged 12 and older with increased bleeding symptoms who remain undiagnosed after standard coagulation testing will be enrolled. They will undergo advanced blood testing for hemostasis and genetic analysis. Participants will also complete questionnaires assessing bleeding symptoms and quality of life. The study will follow participants for up to 10 years to observe changes over time and to evaluate healthcare delivery and patient outcomes. During the study, participants will have blood samples taken for detailed laboratory analyses and will provide information through validated questionnaires. Researchers will assess bleeding symptoms, bleeding severity, physical activity, patient activation, and satisfaction with care, among other outcomes. The study also includes evaluations of diagnostic delays and responses to hemostatic challenges. This long-term observation will help identify subgroups within BDUC and develop improved care pathways based on collected clinical, laboratory, and patient-reported data.
CONDITIONS
Bleeding Disorder of Unknown Cause in the Netherlands
D
Dr. F.C.J.I. Heubel-Moenen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maastricht University Medical Center
Lead Sponsor
Sanquin Research & Blood Bank Divisions
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit for eligibility assessment
Duration - Up to 10 years
Participants undergo blood sampling for advanced hemostasis and genetic testing and complete questionnaires about bleeding symptoms and quality of life. Researchers collect clinical data and follow participants over 10 years.
Periodic visits for blood draws and questionnaire completion
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
A L L Monard, D Hellenbrand, P Verhezen...
https://pubmed.ncbi.nlm.nih.gov/40680469/Dino Mehic, Stephan Schwarz, Ihor Shulym...
https://pubmed.ncbi.nlm.nih.gov/37720482/Stephen MacDonald, Alfie Wright, Frederik Beuche...
https://pubmed.ncbi.nlm.nih.gov/31747136/Tirsa T van Duijl, Samantha Gouw, Ina Kronevska...
https://pubmed.ncbi.nlm.nih.gov/41356341/Amaury L L Monard, Caroline M A Mussert, Tirsa T van Duijl...
https://pubmed.ncbi.nlm.nih.gov/39687924/Caroline M A Mussert, Amaury L L Monard, Tirsa T van Duijl...
https://pubmed.ncbi.nlm.nih.gov/40421900/Will Thomas, Kate Downes, Michael J R Desborough
https://pubmed.ncbi.nlm.nih.gov/33094877/Ross I Baker, Philip Choi, Nicola Curry...
https://pubmed.ncbi.nlm.nih.gov/38518896/Floor C J I Heubel-Moenen, Sanne L N Brouns, Linda Herfs...
https://pubmed.ncbi.nlm.nih.gov/35001370/Maastricht University Medical Center
Lead Sponsor
Sanquin Research & Blood Bank Divisions
Collaborating Sponsor